New Standards and Challenges in the Management of Multiple Myeloma

New Standards and Challenges in the Management of Multiple Myeloma

Program Summary

The rapid advancements in diagnosis, prognosis, and therapeutic options for the management of patients with multiple myeloma have the potential to enhance clinical outcomes and patient quality of life. While new and emerging drug regimens will provide much needed additional options for patients with MM, many questions arise regarding timing, sequencing, and combination therapy. To provide optimal care, healthcare professionals need expert guidance to improve their understanding of how current and novel treatment modalities can be utilized in the most effective way and their ability to plan strategies to incorporate them into everyday clinical practice. Analysis of various clinical scenarios, interpretation of clinical trials and discussion with myeloma experts would help to guide clinical decisions in the rapidly changing landscape of MM

The engaging, interactive activity will feature a nationally recognized expert and is designed to help practicing clinicians apply best current practices to challenging cases. A brief overview of recent advances in the treatment of multiple myeloma will be provided, along with a discussion on sequencing and combination strategies. 

Target Audience 

This educational activity is designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with MM.

Educational Objectives

After completing this program, participants should be able to:

1. Utilize evidence-based management strategies to optimize the treatment of patients with smoldering myeloma, newly diagnosed myeloma, and relapsed/refractory myeloma

2. Formulate the most favorable treatment plan for the individualized management of myeloma, including standard-of-care and emerging regimens for primary therapy, consolidation therapy, and maintenance therapy in both transplant-eligible and transplant-ineligible patients

3. Apply knowledge gained from finalized and ongoing clinical trials to prescribe the best treatment for myeloma patients at the time of first relapse and beyond, including sequencing considerations

4. Evaluate new classes of therapeutics for myeloma, including an understanding of the underlying disease characteristics that impact treatment response

5. Assess limitations in the treatment of multiple myeloma, including considerations for patients with comorbidities or advanced age, to improve treatment outcomes 
Accreditation Information:

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this live activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this live activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Speaker List:

Jonathan Kaufman, MD (Chair)
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Winship Cancer Institute of Emory University

Agne Paner, MD
Division of Oncology & Hematology  
Department of Internal Medicine
Rush University Medical Center
Chicago, IL

Ajay K. Nooka, MD, FACP
Assistant Professor
Division of Bone Marrow Transplant
Winship Cancer Institute of Emory University 
Atlanta, Georgia 
This activity is supported by educational grants from AbbVie, Amgen, Millennium Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Categories: Hospital Events

Don't have an account yet? Register Now!

Sign in to your account